A total of 339 Private Equity/Venture Financing deals (pending and completed) were announced in the Pharmaceuticals of the Asia-Pacific region, in the last twelve months resulting in a total deal value of over $16,941.1 million. In the LTM period, August 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $3,947.2 million, resulting in an average deal value of $103.9 million during that month. On the other hand, the month of January 2022 was the most prolific in terms of deal volume, recording a total of 38 deals, resulting in an average deal value of $28.0 million during that month.
Of the 339 deals, the deal secured between CBC Group and Hugel Inc, was the largest Private Equity/Venture Financing deal in the Asia-Pacific Pharmaceuticals sector, which was valued at $1,500.0 million and was completed on August 27, 2021. The second-largest deal was between FountainVest Partners and Beijing Zhendong Langdi Pharmaceutical Co Ltd, while the third-largest deal was between 5Y Capital; AIHC Capital Management Limited; Alwin Capital; BioTrack Capital; Boyu Capital Consultancy Co. Ltd; CTS Capital Advisors LLC; Firstred Capital; Gaorong Capital; GL Ventures; HighLight Capital (China); Invesco Developing Markets Fund; Kaiser Permanente Ventures; Legend Capital Co Ltd; Lilly Asia ventures; Loyal Valley Capital; MSA Capital; Octagon Capital Group LLC; Oriental Spring; PICC Capital Equity Investment Co Ltd; Qiming Venture Partners; Temasek Holdings (Private) Ltd; Tiger Jade Capital LLP; Winfast Holding; Yingke PE; Youshan Capital; Yunfeng Capital and Suzhou Abogen Biosciences Co Ltd. The FountainVest Partners-Beijing Zhendong Langdi Pharmaceutical Co Ltd deal and the 5Y Capital; AIHC Capital Management Limited; Alwin Capital; BioTrack Capital; Boyu Capital Consultancy Co. Ltd; CTS Capital Advisors LLC; Firstred Capital; Gaorong Capital; GL Ventures; HighLight Capital (China); Invesco Developing Markets Fund; Kaiser Permanente Ventures; Legend Capital Co Ltd; Lilly Asia ventures; Loyal Valley Capital; MSA Capital; Octagon Capital Group LLC; Oriental Spring; PICC Capital Equity Investment Co Ltd; Qiming Venture Partners; Temasek Holdings (Private) Ltd; Tiger Jade Capital LLP; Winfast Holding; Yingke PE; Youshan Capital; Yunfeng Capital-Suzhou Abogen Biosciences Co Ltd deal were valued at $900.0 million and $700.0 million, respectively. The fourth-largest deal was between BGH Capital Pty Ltd-Virtus Health Ltd valued at $519.1 million, whereas the deal between Aztiq Pharma Partners-Alvogen Emerging Markets Holdings Ltd valued at $500.0 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $4,119.1 million and accounted for nearly 24.31% of the total deals (by value) announced during the last twelve months. The Asia-Pacific region accounted for 21.07% of the total Private Equity/Venture Financing deals done globally, and accounted for 4.23% of the total deal size on a global scale.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward